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Abstract Subcutaneous human IgG (SCIG) therapy in
primary immunodeficiency (PID) offers sustained IgG
levels throughout the dosing cycle and fewer adverse
events (AEs) compared to intravenous immunoglobulin
(IVIG). A phase I study showed good local tolerability of
IgPro20, a new 20% liquid SCIG stabilized with L-proline.
A prospective, open-label, multicenter, single-arm, phase
III study evaluated the efficacy and safety of IgPro20 in
patients with PID over 15 months. Forty-nine patients (5–
72 years) previously treated with IVIG received weekly
subcutaneous infusions of IgPro20. The mean serum IgG
level was 12.5 g/L. No serious bacterial infections were
reported. There were 96 nonserious infections (rate 2.76/
patient per year). The rate of days missed from work/school
was 2.06/patient per year, and the rate of hospitalization
was 0.2/patient per year. Ninety-nine percent of AEs were
mild or moderate. No serious, IgPro20-related AEs were
reported. IgPro20 effectively protected patients with PID
against infections and maintained serum IgG levels without
causing unexpected AEs.
Keywords Subcutaneous immunoglobulin (SCIG).
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Introduction
Common variable immunodeficiency (CVID) and X-linked
agammaglobulinemia (XLA) are primary immunodeficiency
(PID) disorders that predispose patients to recurrent infec-
tions and chronic lung disease [1–6]. Patients require
immunoglobulin replacement therapy, which can be admin-
istered intravenously (IVIG) or subcutaneously (SCIG) [7–
14]. Subcutaneous administration produces stable serum IgG
levels and is associated with fewer systemic adverse events
(AEs). Although head-to-head studies have not been
performed, retrospective analyses and two crossover trials
have demonstrated a lower incidence of systemic AEs in
patients receiving SCIG compared to IVIG [15–23]. Recent-
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infusion and home therapy, both offering greater flexibility to
patients [20].
IgPro20 is a new 20% liquid SCIG product with high
purity (≥98% IgG) manufactured from human plasma of
more than 15,000 donors by a process identical to that of
IgPro10 (Privigen®), which has an established rigorous
pathogen safety profile [24]. The high IgG concentration in
IgPro20 allows for infusion of lower volumes compared to
currently available 16% IgG products administered at
equivalent dose. This potentially solves an existing problem
with SCIG therapy for some patients, namely, the number of
infusion sites or doses required to provide adequate IgG
replacement. Despite high protein concentration, IgPro20 has
outstanding solution properties and can be administered at
relatively high infusion rates–a substantial technical achieve-
ment. Formulation with L-proline and Polysorbate 80 allows
storage of IgPro20 for up to 24 months at 25°C without any
loss of functional activity (Maeder et al., in preparation).
We report results on local tolerability in healthy
volunteers from a phase I study, as well as efficacy and
tolerability of IgPro20 in patients with PID from a recently
completed prospective, open-label, multicenter, single-arm,
phase III study (NCT00419341).
Methods
Phase I Local Tolerability Study in Healthy Subjects
Subjects
Twenty-eight healthy, male, white subjects aged 18 to
45 years were recruited. Inclusion criteria included a body
mass index (BMI) of 21–27 kg/m
2, no clinically significant
medical history, and good health (as determined by a
detailed medical history, complete physical examination,
electrocardiogram, and clinical laboratory screening). Sub-
jects were excluded in case of evidence of any clinically
relevant pathology that could interfere with the study
results or put the subject’s safety at risk.
This study was conducted in accordance with the
International Conference on Harmonization (ICH) Good
Clinical Practice (GCP) guidelines, and the Declaration of
Helsinki (version of 1996). The study protocol and all other
study documents were approved by the relevant Indepen-
dent Ethics Committees. Subjects signed an informed
consent prior to entering the study.
Study Design
This was a single-center, randomized, four-way crossover,
assessment-blinded study. The study objective was to
compare the local tolerability of IgPro16 and IgPro20 with
Vivaglobin®.
IgPro16 and IgPro20 are 16% and 20% liquid human
IgG products, respectively, formulated with 28.8 mg/mL
(250 mmol/L) of L-proline and 20 mg/L of Polysorbate 80
at pH 4.8; Vivaglobin® is a 16% liquid human IgG
formulated with 22.5 mg/mL (300 mmol/L) of glycine at
pH 6.4–7.2. Each patient received a single subcutaneous
dose of IgPro16 15 mL, IgPro20 15 mL, IgPro20 12 mL, or
Vivaglobin 15 mL at a single abdominal site on day 1 at
25 mL/h. The next test samples were administered at
weekly intervals at different abdominal sites.
The primary end point was assessment of local
tolerability from the start of infusion to 72 hours after
the end of infusion. Local tolerability included pain
(assessed by subjects), erythema, edema/induration, itch-
ing, and local heat (assessed by a treatment-blinded
investigator).
Tolerability Assessments
Assessments were performed by treatment-blinded inves-
tigators after the end of infusions. Erythema and edema
were evaluated using 5-point scales ranging from none
(score 0) to severe (score 4). Itching and local heat were
evaluated using a 4-point scale ranging from none (score 0)
to severe (score 3). Pain was evaluated by the subjects
using a 100-mm Visual Analogue Scale (VAS) ranging
from 0 (no pain) to 100 (unbearable pain).
The results of the assessments of local tolerability
parameters were not documented as AEs. Local reactions
were recorded as AEs when the symptoms/signs led to
infusion stop, required concomitant medication, or had an
impact on the general condition of the subject as judged by
the investigator.
Phase III Efficacy and Safety Study in Patients With PID
Patients
Males or females aged 5 to 72 years diagnosed as having
CVID, as defined by the Pan-American Group for Immu-
nodeficiency and European Society for Immunodeficien-
cies, or XLA, as determined by the investigator, were
enrolled in the study. Patients were receiving IVIG therapy
at regular 3- or 4-week intervals for at least 3 months prior
to study start. Patients switching from a Privigen study in
PID (NCT00322556) were required to have had at least
three documented serum IgG trough levels of ≥5 g/L for the
last 3 months prior to enrollment in this study. Patients
treated with other IVIG products were required to have had
at least one documented serum IgG trough level of ≥5 g/L
during the previous 6 months.
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viously untreated with IVIG), evidence of an active serious
infection, malignancies of lymphoid cells and immunode-
ficiency with thymoma, known hyperprolinemia, hypoal-
buminemia, protein-losing enteropathies, any proteinuria,
allergic reactions to immunoglobulins or other blood
products, known antibodies to IgA, treatment with steroids
(oral or parenteral, ≥0.15 mg of prednisone equivalent/kg
per day) or other systemic immunosuppressants, pregnancy,
breast feeding planned pregnancy during the course of the
study, and any condition that was likely to interfere with
evaluation of the study medication or satisfactory conduct
of the study.
This study was conducted in accordance with the ICH
GCP guidelines and the Declaration of Helsinki (version of
1996). The study protocol and all other study-related
documents were reviewed and approved by the appropriate
local institutional review boards. Written informed consent
was obtained from all patients or patients’ parents or legal
guardians.
Study Design
This was a prospective, open-label, multicenter, single-arm,
phase III study with a 12-week wash-in/wash-out period
followed by a 12-month efficacy period. Within the main
study, a two-part pharmacokinetic substudy was conducted
in a subset of patients (n=19). Apart from evaluation of
IgPro20 pharmacokinetic parameters, the pharmacokinetic
substudy provided data for dose adjustments in the efficacy
period of the main study.
The initial weekly dose of IgPro20 administered during
the wash-in/wash-out period was the calculated average
weekly dose of the last three IVIG infusions received prior
to the start of this study, multiplied by 1.30, a dose
adjustment coefficient used in a study with Vivaglobin
[25]. In the efficacy period, patients not participating in the
pharmacokinetic substudy had their IgPro20 doses adjusted
by applying a mean dose adjustment coefficient of 1.53,
calculated from individual dose adjustments in pharmacoki-
netic patients (Wasserman et al., manuscript in preparation).
Premedication taken on the same day prior to infusion to
reduce AEs associated with SCIG infusion was not
allowed. Oral and parenteral steroids as concomitant
medication were allowed if the average daily dose was
<0.15 mg of prednisone equivalent/kg per day. Local
anesthetics could be used before infusion to reduce the
pain associated with needle insertion if required.
IgPro20 was administered subcutaneously using Cane
Crono PCA-50 infusion pumps (Cane S.R.L., Turin, Italy).
Potential injection sites were located on the abdomen,
thighs, upper arms, and/or lateral hip, with actual injection
points changed every week. Up to four injection sites were
used simultaneously with a maximum of two pumps, each
with bifurcated tubing feeding two catheters. The initial
volume per injection site was 15 mL and could be increased
to a maximum of 25 mL, depending on tolerability. The
infusion rate was to be ≤15 mL/h per site for the first
infusion and could subsequently be increased stepwise up
to 25 mL/h per site depending on tolerability.
The first three infusions were supervised and served as
training for the patients or their parents/guardians. Patients
administered further infusions themselves, with supervised
infusions during each study site visit (first four infusions
and every fourth infusion thereafter).
Efficacy and Safety Assessments
The primary efficacy end point was the annual rate of serious
bacterial infections (SBIs) per patient in the modified
intention-to-treat (MITT) population comprising all subjects
treated with study medication during the efficacy period
(starting with Week 13). Target rate of SBIs was 1.0 SBI per
patient per year, as recommended by the Food and Drug
Administration (FDA) [26]. SBIs were defined as bacterial
pneumonia, bacteremia/septicemia, osteomyelitis/septic ar-
thritis, bacterial meningitis, and visceral abscess. Each AE
identified as a potential SBI was retrospectively adjudicated
by a review committee to determine whether the event
fulfilled the predefined criteria for SBIs.
Secondary efficacy end points included rate of SBIs in
the ITT population, number of infection episodes, number
of days missed from work/school/day care or inability to
perform normal activities due to infections (abbreviated
further as number of days missed from work/school),
number of days of hospitalization due to infections, use of
antibiotics for infection prophylaxis or treatment, and
trough serum IgG levels. Information about secondary
efficacy end points was collected via patient diaries. Trough
serum IgG levels were measured before every infusion
administered at the study site (every 4 weeks).
Information on AEs, including local reactions, was
collected continuously by patients (diary) and investigators
(at visits).
For the analysis of local reactions, the category of local
reactions was created as derived from the MedDRA
category “General disorders and administration site con-
ditions” and combined the following MedDRA preferred
terms: injection site reaction, injection site bruising,
infusion site scab, injection site cyst, injection site eczema,
injection site irritation, injection site nodule, and injection
site pain. Local reactions were assessed by both patients
and investigators. Patients assessed the overall perception
of local reactions at 24±3 hours after the end of infusion
via diaries, using a 5-point scale (0=none, very slight,
slight, moderate, severe). Appropriate completion of the
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Investigators evaluated local reactions (erythema, edema/
induration and itching, local pain, and local heat) indepen-
dently at 15–45 minutes postinfusion for the first four
infusions at the study site and at every visit to the study site
thereafter, using symptom-specific 5-point scales, except
for edema, which was measured using two diameters in
mm.
Vital signs, including blood pressure, heart rate, and
body temperature, were evaluated at screening and before
and after each infusion administered at the study site (first
four infusions and every fourth infusion thereafter).
Clinical laboratory parameters were determined at screen-
ing; before infusions 1, 4, 28, and 40; and at the
completion visit.
A direct Coombs’ test was performed before and shortly
after infusions 1 and 4, on day 3 of week 28, before and
after infusion 64, 2 or 3 days after infusion 64, and at the
completion visit. If a positive direct Coombs’ test result was
accompanied by a decrease of ≥2.0 g/dL in hemoglobin
compared to the preinfusion 64, then the test results were
followed-up by extensive additional testing. A decrease of
≥2.0 g/dL in hemoglobin together with an increase in
lactate dehydrogenase and a decrease in serum haptoglobin
were considered indicative of a potential intravascular
hemolysis.
Statistical Methodology
A sample size of 32 patients was calculated to provide 80%
power of detecting SBIs, provided the true SBI rate was
0.5. To allow for a moderate to high discontinuation rate, a
sample size of 50 patients was planned.
Efficacy analyses were carried out on the MITT
population. Safety analyses were carried out in the ITT
population, defined as all subjects treated with the study
medication during the entire study period.
Efficacy analyses were restricted to the efficacy period
(week 13–to completion visit). The annual rate of SBIs per
patient was estimated along with its upper one-sided 99%
confidence interval (CI). The number of infection episodes
was estimated with two-sided 95% CIs. Variables
concerning demographic and background characteristics
and secondary efficacy variables were summarized descrip-
tively. No imputation of missing data was made.
Results
Phase I Local Tolerability Study in Healthy Subjects
All 28 subjects randomized completed the study.
The mean (±SD) age of subjects was 34 (±5.97) years
(range 22–45 years). The mean (±SD) body weight (bw)
was 75.5 (±7.4) kg, with a mean (±SD) BMI of 23.4 kg/m
2
(±1.58 kg/m
2).
The subjective assessment of pain associated with
infusion based on the 100 mm VAS scale was very low
(Table 1). Both maximum pain and mean pain were lower
with IgPro20 compared to Vivaglobin. Treatment differ-
ences for mean pain were statistically significant for
IgPro16 and IgPro20 (12 mL) versus Vivaglobin (p=
0.0328 and p=0.0205, respectively).
Table 1 Local Tolerability: Pain (Healthy Subjects)
Variable IgPro16 (15mL) IgPro20 (15mL) IgPro20 (12mL) Vivaglobin (15mL)
Subjects treated
a 28 (100%) 28 (100%) 28 (100%) 28 (100%)
Maximum pain
b (mm), mean (SD) 6.8 (12.52) 7.6 (12.46) 6.9 (12.13) 9.3 (14.18)
Mean pain
b (mm), mean (SD) 2.36 (5.029) 2.84 (3.612) 2.24 (4.240) 3.78 (7.244)
Variable Comparison Difference
c Two-sided 90% CI (p)
Maximum pain
b (mm) IgPro16 (15 mL)–Vivaglobin -2.54 -4.82 to -0.26 (0.0679)
IgPro20 (15 mL)–Vivaglobin -1.64 -3.92 to 0.64 (0.2340)
IgPro20 (12 mL)–Vivaglobin -2.43 -4.71 to -0.15 (0.0801)
Mean pain
b (mm) IgPro16 (15 mL)–Vivaglobin -1.41 -2.50 to -0.33 (0.0328)
IgPro20 (15 mL)–Vivaglobin -0.94 -2.02 to 0.15 (0.1545)
IgPro20 (12 mL)–Vivaglobin -1.54 -2.62 to -0.46 (0.0205)
aResults represent number of subjects (%).
bPain was assessed by subjects on a 100-mm VAS; numbers given are from that scale.
cA negative difference indicates a generally higher value of maximum/mean pain under Vivaglobin.
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defined” or “very slight” (Table 2). Overall, the intensity
of erythema was less severe with IgPro20 than with
Vivaglobin. While a third of the events with IgPro20 were
“very slight” and less than 57% were “well-defined,” 75%
of the events observed with Vivaglobin were “well-
defined.” At the end of the scheduled observation period
on day 4, no erythema was observed in 94 (84%) out of 112
evaluations.
Almost all subjects experienced severe edema/
induration (Table 2), as expected in a subcutaneous
infusion. On day 2, 24 hours after the end of infusion, no
edema/induration was observed in 31 (28%) of 112
evaluations. At the end of the scheduled observation
period on day 4, no edema/induration was observed in
79 (71%) of 112 evaluations.
Itching was predominantly mild (Table 2). In only
15 of 112 evaluations (13%), subjects reported mild
local heat, with no substantial difference between
IgPro16, IgPro20 (12 mL), and Vivaglobin (15 mL).
Local heat started to occur during the infusion and was
resolved shortly after the end of infusion. Eight hours
after the end of infusion, all reported cases of local heat
were resolved.
None of the observed local tolerability events had the
characteristics of predefined AEs.
Thus, in a phase I trial, IgPro20 was not inferior in its
safety and tolerability when compared to Vivaglobin.
Phase III Efficacy and Safety Study in Patients with PID
Patients
This phase III study in patients with PID was conducted at
12 sites in the United States. Fifty-two patients were
screened, 49 enrolled, 38 completed the wash-in/wash-out
period (11 discontinued), and 28 completed the efficacy
period (10 discontinued).
The reasons for discontinuation of patients during the
wash-in/wash-out period were withdrawal of consent (n=
8), AEs (n=2), and disqualifying laboratory results (n=1);
the reasons for discontinuation of patients during the
efficacy period were withdrawal of consent (n=6), termi-
nation of study site (n=1), multiple violations of protocol
(n=1), lost to follow-up (n=1), and noncompliance (n=1).
Patients who withdrew consent gave the following individ-
ual motives for their decision: study time commitment
(including weekly site visits in the beginning and/or a
IgPro16 (15mL) IgPro20 (15mL) IgPro20 (12mL) Vivaglobin (15mL)
Subjects treated
a 28 (100) 28 (100) 28 (100) 28 (100)
Erythema 23 (82.1) 26 (92.9) 27 (96.4) 28 (100)
None 5 (17.9) 2 (7.1) 1 (3.6) –
Very slight 9 (32.1) 9 (32.1) 11 (39.3) 4 (14.3)
Well-defined 12 (42.9) 14 (50.0) 16 (57.1) 21 (75.0)
Moderate to severe 2 (7.1) 2 (7.1) – 3 (10.7)
Severe – 1 (3.6) ––
Edema/Induration 28 (100) 28 (100) 28 (100) 28 (100)
None ––––
Very slight ––––
Slight ––––
Moderate 1 (3.6) –––
Severe 27 (96.4) 28 (100) 28 (100) 28 (100)
Itching 10 (35.7) 14 (50.0) 11 (39.3) 16 (57.1)
None 18 (64.3) 14 (50.0) 17 (60.7) 12 (42.9)
Mild 10 (35.7) 13 (46.4) 10 (35.7) 14 (50.0)
Moderate – 1 (3.6) 1 (3.6) 2 (7.1)
Severe ––––
Local heat 5 (17.9) 1 (3.6) 5 (17.9) 4 (14.3)
None 23 (82.1) 27 (96.4) 23 (82.1) 24 (85.7)
Mild 5 (17.9) 1 (3.6) 5 (17.9) 4 (14.3)
Moderate ––––
Severe ––––
Table 2 Local Tolerability:
Incidence of Local Reactions
(Healthy Subjects)
For each subject only the high-
est severity per period is taken
into account.
aResults represent number of
subjects (%).
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issues present while receiving IVIG treatment and not
resolved on SCIG (n=4), feeling too good and not wanting
to be reminded about the disease by weekly infusions (n=
2), and compliance issues (n=1).
Patients’ mean age was 36 years, including three
children and three adolescents, and the proportion of males
and females was similar (Table 3). Most of the patients had
CVID; 32 patients had been diagnosed more than 2 years
prior to the study. Two patients had XLA diagnosed more
than 2 years prior to the study.
Study Drug Administration
All 38 MITT subjects received the intended 12 infusions
during the wash-in/wash-out period. During the efficacy
period, 23 subjects (60.5%) received the planned 54 infusions,
and15subjects(39.5%)receivedbetween11and53infusions.
The mean IgPro20 dose during the wash-in/wash-out
period ranged from 176.8 to 182.9 mg/kg bw per week. In
the efficacy period, starting at week 13, the mean IgPro20
dose was 179.6 to 224.3 mg/kg bw per week.
Median infusion rate (total body) was 25 mL/h during
the wash-in/wash-out period (range 15.0–50.0 mL/h) and
50 mL/h during the efficacy period (range 15.0–50.0 mL/
h). Mean (±SD) infusion rates (total body) were 30.9 mL/h
(±12.49) and 39.1 mL/h (±13.41), respectively. The overall
median infusion duration was 2.0 hours (range 0.5–
17.0 hours).
Efficacy
Primary Efficacy End Point No SBIs, as defined by the
FDA, were observed in the MITT population in this
study. The annual rate of SBIs per patient was 0 (upper
99% CI 0.132), and thus, the study objective was
achieved (Table 4). There were no SBIs in the ITT
population either.
Five AEs in three patients with CVID were examined
closely by the review committee before identifying them
as non-SBIs. In a 71-year-old woman, pneumonia was
suspected twice during hospitalization for cellulitis and
urinary tract infection (both serious AEs [SAEs]). In the
first case, the diagnosis of pneumonia was rejected, as
two x-rays and a computerized tomography (CT) chest
scan did not reveal changes consistent with bacterial
infection in lungs; repeat blood cultures were negative.
The possibility of second pneumonia was raised because
of nonproductive cough and focal areas of opacity in
chest x-ray and CT scan. Pneumonia was rejected at the
diagnosis because of the lack of new respiratory
symptoms, normal white blood cell count, as well as
negative bronchoalveolar lavage, Gram stain, and viral
antigen panel results. In the same patient, an AE of
suspected bacteremia during hospitalization for cellulitis
was determined not to meet the criteria for SBI because
an initial finding of Staphylococcus epidermidis, attribut-
ed to contaminated central venous catheter, was followed
by multiple negative blood cultures and was not accom-
panied by the required diagnostic criteria for bacteremia/
septicemia. In a 60-year-old woman, an S. epidermidis
infection during hospitalization for gastroenteritis (an
SAE) was a suspected SBI of bacteremia, but because
the single finding of infection associated with contami-
nated central venous catheter was followed by several
sterile cultures and not accompanied by the required
diagnostic criteria for bacteremia, the event was not
considered an SBI. In a 17-year-old girl, an AE of
pneumonia was not felt to meet SBI criteria. Although
she was seen by her primary care physician for symptoms
of cough and noted to have fever and crackles, none of the
essential diagnostic features were present: productive
cough, dyspnea or tachypnea, chills, chest pain, rigors,
Table 3 Demographic and Baseline Characteristics (Patients with
PID)
Characteristic MITT population (N=38)
Gender, n (%)
Female 21 (55.3)
Male 17 (44.7)
Age (years)
Mean (SD) 36.3 (19.52)
Median (range) 36.5 (5–72)
Age group, n (%)
5–11 years 3 (7.9)
12–15 years 3 (7.9)
16–64 years 28 (73.7)
65–72 years 4 (10.5)
Race or ethnic group, n (%)
White 37 (97.4)
Black or African American 1 (2.6)
Hispanic or Latino
a 2 (5.3)
Weight (kg)
Mean (SD) 70.0 (21.34)
Median (range) 70.0 (21–104)
Primary disease
CVID, n (%) 36 (95)
XLA, n (%) 2 (5)
Median serum IgG trough level
b, g/L
Mean (SD) 10.1 (2.57)
aEthnic groups were summarized independently of race.
bIndividual median values during the last 3 months of treatment with IVIG
prior to this study.
J Clin Immunol (2010) 30:734–745 739headache, and sweats were absent; there was no dullness
to percussion; white blood count was normal; hypoxemia
was not found. Although a chest x-ray and blood or
sputum cultures were not done, a throat swab sent for a
rapid strep test was negative.
Secondary Efficacy End Points A total of 96 non-SBI
infection episodes were observed in 31 (81.6%) patients,
resulting in an annual rate of 2.76 per patient (95% CIs
2.235–3.370) (Table 4). Sinusitis was the most common
infection experienced by 12 patients, followed by naso-
pharyngitis in 6 patients (14 and 11 patients in the ITT
population, respectively).
Twelve patients (31.6%) missed 71 days from work/
school (annual rate 2.06 per patient). A single patient was
hospitalized for 7 days due to infections in the period
between weeks 44 and 47 (annual rate 0.2 per patient). In
total, 27 patients (71.1%) spent 1,688 days on antibiotics
(annual rate 48.5 days per patient) for treatment of AEs,
prophylaxis, or medical/surgical/current conditions; 25
patients were treated for AEs during 1,040 days (annual
rate 29.9 days per patient), and 2 patients had antibiotic
prophylaxis for 16 days (annual rate 0.5 days per patient).
Nine patients (23.7%) used antibiotics on 664 days for the
treatment of medical/surgical/current conditions, and one
patient was treated with antibiotics for other indications
(9 days).
In the MITT population, the mean (±SD) of the individual
median IgG trough levels was 12.56 g/L (±2.92 g/L) during
thewash-in/wash-outperiodand12.53g/L(±3.21g/L)during
the efficacy period. Serum IgG levels stabilized by the end of
the wash-in/wash-out period, when patients’ individual doses
were adjusted as described. Overall, mean serum IgG trough
levels in the efficacy period were maintained between 12.1
and 12.9 g/L (Fig. 1).
Safety and Tolerability
Local Reactions As expected, local reactions were ob-
served in all 49 patients in the ITT population: 1,340 events
were recorded during the 2,264 infusions, resulting in a rate
Fig. 1 Serum IgG trough levels (patients with PID). Blood samples
were taken before infusion start at screening (S); at weeks 1, 2, 3, 4, 8,
and 12; every 4 weeks thereafter; and at the completion visit (CV). For
most infusions and for the completion visit, data from at least 29
patients were available; for the following infusions, the number of
patients with available data was lower: infusion 60, n=28; infusion 64,
n=27. Note that the patient’s regular IVIG infusion was given just
after screening, and SCIG administration was begun 1 week later
Efficacy end point Number (%) of patients Number (annual rate)
of events/days [CI]
Total no. of patients/study days N=38 N=12,697
a
SBIs [upper 99% CI] 0 (0) 0 (0)
[0.132]
Total no. of patients/study days N=38 N=12,697
a
Infection episodes (nonserious) [95% CIs] 31 (81.6) 96 (2.76)
[2.235–3.370]
Total no. of patients/study days N=38 N=12,605
b
Days missed from work/school 12 (31.6) 71 (2.06)
NA
Total no. of patients/study days N=38 N=12,605
b
Days hospitalized due to infection 1 (2.6) 7 (0.2)
NA
Total no. of patients/study days N=38 N=12,697
a
Days with antibiotics for infection prophylaxis
or treatment
27 (71.1) 1,688 (48.5)
NA
Table 4 Primary and Secondary
Efficacy End Points (Patients
with PID; MITT Population)
aTotal number of days in the
study.
bTotal number of days from
patient diaries.
740 J Clin Immunol (2010) 30:734–745of 0.592 events per infusion (Table 5). Of these, 1,322
events were temporally associated AEs (defined as occur-
ring between the start of infusion and 72 hours after the end
of infusion), and 1,338 events were considered at least
possibly related to study medication. The most common AE
was injection site reaction. Most local reactions were mild
in intensity, and only four severe events were observed.
Injection site reactions were predominantly mild (93.4%);
6.3% were moderate and only 0.3% were severe. IgPro20
dose had no effect on the incidence of local reactions (not
shown). According to investigators’ assessments 45 minutes
after infusion, the overall incidence of injection site
reactions remained stable over time (slope of linear
regression line -0.0002), whereas according to patients’
estimates 24 hours after infusion, it showed a slight
tendency to decrease (slope of linear regression line
-0.0018; Fig. 2). This apparent discrepancy may be due to
the different times of assessment (immediate versus
24 hours postinfusion) or to the fact that patients were
reporting less, as they learn to put up with the burdens of
therapy. Patients tolerated the local reactions, and their
assessment of tolerating these appeared to improve over
time.
Overall AEs Excluding local reactions, 45 subjects (91.8%)
had at least one AE, of whom 25 patients (51.0%)
experienced AEs considered at least possibly related to
study medication. Apart from local reactions following
infusions, the most common AE, regardless of relation to
study treatment, was sinusitis, followed by headache and
nasopharyngitis (Table 6). Most common related AEs are
summarized in Table 7. Excluding local reactions, 409 AEs
were reported in the 2,264 infusions administered in the
study, resulting in a rate of 0.181 AEs per infusion. Of
these, 98 AEs were considered at least possibly related to
study medication (rate of 0.043 AEs per infusion).
Almost all AEs were of mild or moderate intensity
(99%). This was true for each of the three most common
AEs as well: 8 of 20 AEs of sinusitis were mild and 12
were moderate; 21 of 40 AEs of headache were mild and 15
were moderate; 13 of 15 AEs of nasopharyngitis were mild
and 2 were moderate. Nineteen severe AEs were reported,
most occurring in one patient each. The most common
severe AEs were headache (in four patients [8.2%]),
injection site reaction (in three patients [6.1%]), and chest
pain (in two patients [4.1%]). Of the 19 severe AEs, 7 were
considered related to study medication (4 infusion site
reactions and 3 headaches).
Serious AEs There were no deaths during the study. Seven
patients (14.3%) experienced 10 SAEs, none of them an
injection site reaction and none assessed as related to study
medication. The SAEs were chest pain (2 events), gastro-
enteritis, obstruction of the small intestine, tooth abscess,
cellulitis, urinary tract infection, decreased hemoglobin,
musculoskeletal stiffness, and papillary thyroid cancer. Six
of the SAEs were severe in intensity. Except for the SAE of
papillary thyroid cancer, all SAEs resolved without sequel-
ae by the final assessment. The SAE of cellulitis was of
moderate intensity and was reported as an SAE because it
Fig. 2 Rate of injection site reactions over time (patients with PID).
Investigator assessments were performed at 15 to 45 minutes after
infusion at study visits (every 4 weeks). Patient assessments were
made 24±3 hours after every infusion until the completion visit (week
66). For both assessments, the number of infusions with available data
decreased from 49 at week 1 to 28 at week 64
Table 5 Local Reactions (Experienced by ≥2 Patients
a with PID; ITT Population)
AE Mild Moderate Severe Total
Local reactions, n (rate)
b 1,251 (0.553) 85 (0.038) 4 (0.002) 1,340 (0.592)
Injection site reaction, n (rate) 1,227 (0.542) 83 (0.037) 4 (0.002) 1,314 (0.580)
Injection site bruising, n (rate) 19 (0.008) 0 0 19 (0.008)
Injection site cyst, n (rate) 2 (<0.001) 0 0 2 (<0.001)
n number of events.
aLocal reactions experienced by one patient each: injection site irritation, injection site nodule, injection site pain, all mild; infusion site scab and injection
site eczema, both moderate
bRate was determined as number of events per infusion. The total number of infusions was 2,264.
J Clin Immunol (2010) 30:734–745 741required hospitalization; it resolved without sequelae after
7 days. According to FDA criteria, cellulitis is not
considered a potential SBI.
AEs Leading to Discontinuation Two patients (4.1%)
discontinued the study due to AEs. One patient, with a
history of atopic dermatitis, asthma, and drug hypersensi-
tivity, experienced a severe injection site reaction with
lesions consistent with giant urticaria. The AE was
considered at least possibly related to study medication; it
resolved without sequelae after 13 days. Another patient
experienced moderate myositis. Although this AE was
Table 6 Most Common AEs (Experienced by ≥5 Patients with PID; ITT Population)
AE All events Temporally associated (72h)
No. (%) of
patients (n=49)
No. (rate) of
events (n=2,264)
No. (%) of
patients (n=49)
No. (rate) of
events (n=2,264)
Any AE 49 (100) 1,749 (0.773) 49 (100) 1,566 (0.692)
Injection site reaction 49 (100) 1,314 (0.580) 49 (100) 1,298 (0.573)
Sinusitis 14 (28.6) 20 (0.009) 7 (14.3) 10 (0.004)
Headache 13 (26.5) 40 (0.018) 12 (24.5) 32 (0.014)
Nasopharyngitis 11 (22.4) 15 (0.007) 8 (16.3) 8 (0.004)
Cough 8 (16.3) 9 (0.004) 5 (10.2) 6 (0.003)
Diarrhea 7 (14.3) 8 (0.004) 5 (10.2) 6 (0.003)
Bronchitis 6 (12.2) 9 (0.004) 5 (10.2) 6 (0.003)
Fatigue 6 (12.2) 6 (0.003) 4 (8.2) 4 (0.002)
Injection site bruising 5 (10.2) 19 (0.008) 5 (10.2) 18 (0.008)
Back pain 5 (10.2) 11 (0.005) 4 (8.2) 5 (0.002)
Acute sinusitis 5 (10.2) 7 (0.003) 4 (8.2) 5 (0.002)
Nausea 5 (10.2) 5 (0.002) 4 (8.2) 4 (0.002)
Abdominal pain upper 5 (10.2) 5 (0.002) 3 (6.1) 3 (0.001)
Upper respiratory tract infection 5 (10.2) 6 (0.003) 3 (6.1) 3 (0.001)
Rash 5 (10.2) 7 (0.003) 2 (4.1) 3 (0.001)
Table 7 Most Common Causally Related AEs (ITT Population)
Infusion-related Infusion-related and temporally
associated (72 h)
AE No. (%) of
patients (n=49)
No. (rate) of
events (n=2,264)
No. (%) of
patients (n=49)
No. (rate) of
events (n=2,264)
Any AE 49 (100) 1,436 (0.634) 49 (100) 1,397 (0.617)
Injection site reaction 49 (100) 1,313 (0.580) 49 (100) 1,297 (0.573)
Headache 12 (24.5) 36 (0.016) 11 (22.4) 31 (0.014)
Injection site bruising 5 (10.2) 19 (0.008) 5 (10.2) 18 (0.008)
Vomiting 3 (6.1) 3 (0.001) 3 (6.1) 3 (0.001)
Pain 3 (6.1) 4 (0.002) 2 (4.1) 3 (0.001)
Fatigue 3 (6.1) 3 (0.001) 2 (4.1) 2 (<0.001)
Contusion 2 (4.1) 3 (0.001) 2 (4.1) 3 (0.001)
Back pain 2 (4.1) 3 (0.001) 2 (4.1) 2 (<0.001)
Diarrhea 2 (4.1) 2 (<0.001) 2 (4.1) 2 (<0.001)
Abdominal pain upper 2 (4.1) 2 (<0.001) 2 (4.1) 2 (<0.001)
Nausea 2 (4.1) 2 (<0.001) 2 (4.1) 2 (<0.001)
Migraine 2 (4.1) 3 (0.001) 1 (2.0) 2 (<0.001)
Rash 2 (4.1) 2 (<0.001) 1 (2.0) 1 (<0.001)
Arthralgia 2 (4.1) 2 (<0.001) 1 (2.0) 1 (<0.001)
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discontinuation because the condition gradually worsened
throughout the study. The patient had highly elevated
alanine aminotransferase, aspartate aminotransferase, and
creatine kinase at screening and a medical history that
included leg pain. The AE was considered at least possibly
related to study medication; it resolved several months after
the final assessment.
Laboratory tests Median values and ranges of hematology
and blood chemistry parameters showed no relevant
changes over time. Most of the individual hematology and
blood chemistry and all urinalysis values lying outside the
normal range were considered by the investigator as not
clinically significant.
No consistent or clinically relevant changes in vital signs
or physical examination were observed. There was no
clinical nor laboratory evidence of acquisition of any blood
borne pathogen associated with study product.
Direct Coombs’ test Forty-five patients had a negative
direct Coombs’ test at baseline, and five patients developed
positive Coombs’ tests at different visits. One of these five
patients had low baseline hemoglobin (not considered
clinically significant), with values normalizing during the
study. The other four patients had hemoglobin within the
normal range throughout the study, except one who had a
value higher than the upper limit of the normal range at the
completion visit (not considered clinically relevant).
No signs of hemolysis were observed in any patient. A
decrease in hemoglobin of ≥2 g/dL was recorded in five
subjects but was not accompanied by a positive direct
Coombs’ result, a decrease in haptoglobin, or an increase in
lactate dehydrogenase.
Discussion
The results of the Phase III study showed ideal efficacy of
the first 20% SCIG IgPro20 in patients with PID. No SBIs
were observed during the entire study period, and the rate
of any infections was very low, 2.76 infections per patient
per year. Mean serum IgG trough levels during the efficacy
period were maintained between 12.1 and 12.9 g/L, which
is within the normal range for healthy individuals. Local
reactions were predominantly mild, and comprehensive
safety monitoring showed no new types of AEs. Overall,
the results of this study showed that IgPro20 is effective
and well tolerated in this patient population. The develop-
ment of a 20% IgG preparation with stable solution
properties is a substantial technical achievement and
represents a serious advance in patient convenience in IgG
replacement therapy.
According to the 2008 FDA bulletin, patients with PID
may experience four or more SBIs per year without
immunoglobulin replacement therapy [26]. Children with
XLA aged 2 to 111 months experienced 0.4 SBIs requiring
hospitalization per patient per year before commencing
immunoglobulin therapy [27]. SCIG products have been
shown to be effective in preventing infections in patients
with PID, with efficacy comparable to that of IVIG
preparations [16]. The main efficacy end point in this
study, the annual rate of SBIs, was 0 (upper 99% CI 0.132)
and thus much lower than the FDA requirement of 1.
Therefore, the primary efficacy objective of the study was
met. This result compares well with the annual rate of 0.04
SBIs per patient obtained with Vivaglobin, the only SCIG
product currently approved for use in the United States [19,
25]. Similar rates were reported also for three 10% liquid
IVIG products. With Gammagard Liquid and Privigen, 0
and 0.08 SBIs per patient per year were observed,
respectively [14, 28]. Despite the different definition of
serious infections used in the study of Gamunex, a similar
number was reported: <0.2 validated sinopulmonary infec-
tions per patient per year [29]. In general, the annual rate of
SBIs in this study is slightly better than the overall mean of
0.068 SBIs per patient per year observed in the licensing
trials of all IVIG preparations approved in the United States
since 2000 [16].
The frequency of any infections observed in this
study, 2.76 infections per patient per year, was lower
than that reported in two Vivaglobin studies (4.43
infections per patient per year [25] and 4.1 respiratory
p e rp a t i e n tp e ry e a r[ 19]) and lower than the combined
mean value of 3.02 nonserious infections observed in the
licensing trials of IVIG preparations approved in the
United States since 2000 [16]. On average, patients missed
2.06 days per patient from work/school, which is lower
than the annual rate of 3.70 days per patient reported for
Vivaglobin [25].
IgPro20 showed very good tolerability with regard to
both local injection site reactions and systemic AEs. Most
(99%) local reactions were mild or moderate, including
injection site reactions, the most common AE, 99.7% of
which were mild or moderate. Similar results were reported
in a study of Vivaglobin performed in the Unites States:
91% of patients experienced infusion site reactions, and
96% of those were mild or moderate [25]. Direct
comparison between IgPro20 and Vivaglobin in healthy
volunteers showed that local tolerability of IgPro20 is
similar to that of Vivaglobin, with a slight improvement in
mean pain scores and intensity of erythema with IgPro20.
Similar local tolerability results were observed with the use
of IgPro16 and IgPro20, which may be attributed to the
inherent qualities of the formulation. Tolerability of
IgPro20 with regard to systemic AEs was also very good.
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experienced temporally associated headache, a typical AE
for immunoglobulin therapy, compared to 48% of patients
treated with Vivaglobin for the same time period (64 weeks)
[25]. Almost all headaches in this study were mild or
moderate (36 of 40, 90%), compared to 20 of the 31
observed with Vivaglobin. Thus, it appears that both the
local and systemic tolerability of IgPro20 was slightly
better than that of Vivaglobin in both healthy subjects and
patients with PID.
The safety profile of IgPro20 is indistinguishable from
that of other immunoglobulin products, with nature,
frequency, and relatedness of AEs typical of disease
and treatment. Overall, the rate of infusion-related AEs
other than local reactions was only 0.043 per infusion.
No hemolysis was observed after IgPro20 administration.
The frequency of typical, temporally associated AEs such
as headache, fatigue, and nausea (Table 6)w a sl e s s
common with IgPro20 than with some recently tested
IVIG preparations. Headache, fatigue, and nausea were
reported by 36.1%, 16.4%, and 9.8% of patients treated
with Gammagard Liquid [28] and by 43.8%, 16.3%, and
12.5% of patients treated with Privigen [14]. The remain-
ing AEs observed with IgPro20 did not differ from AEs
known to be typical for this therapy, and no new AE
syndromes were observed. Immunologists treating adult
patients with IVIG are often concerned over the potential
risk of cardiac or thromboembolic AEs during the extreme
IgG peak after infusion [30–32]. SCIG may provide
additional safety in this respect.
Mean serum IgG levels achieved in this study were
within the normal range for healthy individuals and higher
than the recommended minimal trough level of 5 g/L [33].
In this U.S. study, systemic exposure equivalent to previous
IVIG treatment was targeted, and therefore, a 153% dose
adjustment (to achieve equivalent bioavailability with
SCIG) was performed after the wash-in/wash-out period
(week 12). In a recently completed European study of
IgPro20 in patients with PID, subcutaneous therapy was
started and maintained at weekly doses equivalent to one
fourth of the previous monthly IVIG doses to achieve
comparable serum IgG trough levels, as recommended by
the European Medicines Agency [34]. It remains to be
established whether one of these strategies proves better for
achieving optimal clinical outcomes.
IgPro20 was largely self-administered by patients at
home. The relatively low infusion volumes of subcutaneous
infusions resulted in a median infusion duration of only
2 hours allowing for convenient treatment with the possibil-
ity of improved patient acceptability and possibly improved
compliance. Some patients withdrew consent (14 patients)
due to personal reasons, suggesting that certain patients may
prefer IVIG over SCIG. It has been reported previously that
some patients prefer intravenous to subcutaneous IgG
administration, primarily because they are uncomfortable
with self-infusion or fear facing AEs at home [35]. Thus, the
decision regarding the most appropriate modality of immu-
noglobulin replacement should continue to be individualized
with an understanding of patient-specific preferences as well
as risks and goals of treatment.
In conclusion, IgPro20 is the first 20% SCIG and shows
excellent efficacy and tolerability in patients with PID.
IgPro20 should provide an important alternative for
patients who would like to benefit from convenient self-
administration of immunoglobulin therapy at home.
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